HRP20151001T4 - Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti - Google Patents

Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti Download PDF

Info

Publication number
HRP20151001T4
HRP20151001T4 HRP20151001TT HRP20151001T HRP20151001T4 HR P20151001 T4 HRP20151001 T4 HR P20151001T4 HR P20151001T T HRP20151001T T HR P20151001TT HR P20151001 T HRP20151001 T HR P20151001T HR P20151001 T4 HRP20151001 T4 HR P20151001T4
Authority
HR
Croatia
Prior art keywords
nhc
pyridin
sulfonyl
methyl
piperazin
Prior art date
Application number
HRP20151001TT
Other languages
English (en)
Inventor
Milan Bruncko
Hong Ding
George Doherty
Steven Elmore
Lisa Hasvold
Laura Hexamer
Aaron R. Kunzer
Xiaohong Song
Andrew J. Souers
Gerard Sullivan
Zhi-Fu Tao
Gary T. Wang
Le Wang
Xilu Wang
Michael Wendt
Robert Mantei
Todd M. Hansen
Original Assignee
AbbVie Ireland Unlimited Company, c/o Conyers Corporate Services (Bermuda) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42677657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151001(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Ireland Unlimited Company, c/o Conyers Corporate Services (Bermuda) Limited filed Critical AbbVie Ireland Unlimited Company, c/o Conyers Corporate Services (Bermuda) Limited
Publication of HRP20151001T1 publication Critical patent/HRP20151001T1/hr
Publication of HRP20151001T4 publication Critical patent/HRP20151001T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Claims (6)

1. Spoj, naznačen time, da ima formulu (II) [image] ili njegova terapeutski prihvatljiva sol, gdje R100 je R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, NHR57, N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br ili I; n je 0, 1, 2, ili 3; A1 je N ili C(A2); A2 je H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; B1 je H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; D1 je H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; E1 je H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; i Y1 je H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, SO2R17, NH2, NHR17, N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N(R17)2, NHS(O)R17 ili NHSO2R17; ili E1 i Y1 zajedno s atomima na koje su vezani, čine benzen, naftilen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i A2, B1 i D1 su neovisno odabrani od sljedećih: H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; ili Y1 i B1 zajedno s atomima na koje su vezani, čine benzen, naftilen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i A2, D1 i E1 su neovisno odabrani od sljedećih: H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2ili C(O)OR1A; ili A2 i B1 zajedno s atomima na koje su vezani, čine benzen, naftilen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i D1, E1 i Y1 su neovisno odabrani od sljedećih: H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; ili A2 i D1 zajedno s atomima na koje su vezani, čine benzen, naftalen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i B1, E1 i Y1 su neovisno odabrani od sljedećih: H, R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NH2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2NHR1, NHSO2N(R1)2, NR1SO2NHR1, NR1SO2N(R1)2, C(O)NHNOH, C(O)NHNOR1, C(O)NHSO2R1, C(NH)NH2, C(NH)NHR1, C(NH)N(R1)2 NHSO2NHR1, NHSO2N(CH3)R1, N(CH3)SO2N(CH3)R1, F, Cl, Br, I, CN, NO2, N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3, C(O)OH, C(O)NH2 ili C(O)OR1A; R1 je R2, R3, R4 ili R5; R1A je cikloalkil, cikloalkenil ili cikloalkinil; R2 je fenil koji je nestaljen ili staljen s R2A; R2A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R3 je heteroaril koji je nestaljen ili staljen s R3A; R3A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R4 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R4A; R4A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R5 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br i I; R6 je C2-C5-spiroalkil od kojih je svaki nesupstituiran ili supstituiran s OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) ili N(CH3)2; R6A i R6B su neovisno odabrani od alkila; R7 je R8, R9, R10 ili R11; R8 je fenil koji je nestaljen ili staljen s R8A; R8A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R9 je heteroaril koji je nestaljen ili staljen s R9A; R9A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R10 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R10A; R10A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R11 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R12 je R13, R14, R15 ili R16; R13 je fenil koji je nestaljen ili staljen s R13A; R13A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R14 je heteroaril koji je nestaljen ili staljen s R14A; R14A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R15 je cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken, od kojih je svaki nestaljen ili staljen s R15A; R15A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R16 je alkil, alkenil ili alkinil; R17 je R18, R19, R20 ili R21; R18 je fenil koji je nestaljen ili staljen s R18A; R18A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R19 je heteroaril koji je nestaljen ili staljen s R19A; R19A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R20 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R20A; R20A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R21 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R22, OR22, SR22, S(O)R22, SO2R22, C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, NHR22, N(R22)2, NHC(O)R22, NR22C(O)R22, NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)NHR22, NHC(O)N(R22)2, NR22C(O)NHR22, NR22C(O)N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, C(O)NHOH, C(O)NHOR22, C(O)NHSO2R22, C(O)NR22SO2R22, SO2NH2, SO2NHR22, SO2N(R22)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR22, C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R22 je R23, R24 ili R25; R23 je fenil koji je nestaljen ili staljen s R23A; R23A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R24 je heteroaren koji je nestaljen ili staljen s R24A; R24A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R25 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R25A; R25A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; Z2 je R28, R29 ili R30; L1 je R37, OR37, SR37, S(O)R37, SO2R37, C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, NHR37, C(O)NH, C(O)NR37, C(O)NHOR37, C(O)NHSO2R37, SO2NH, SO2NHR37, C(N)NH ili C(N)NHR37; R28 je fenilen koji je nestaljen ili staljen s R28A; R28A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R29 je heteroarilen koji je nestaljen ili staljen s R29A; R29A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R30 je cikloalkilen, cikloalkenilen, heterocikloalkilen ili heterocikloalkenilen, od kojih je svaki nestaljen ili staljen s R30A; R30A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R37 je veza ili R37A; R37A je alkilen, alkenilen ili alkinilen, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R37B, OR37B, SR37B, S(O)R37B, SO2R37B, C(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, NHR37B, N(R37B)2, NHC(O)R37B, NR37BC(O)R37B, NHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)NHR37B, NHC(O)N(R37B)2, NR37BC(O)NHR37B, NR37BC(O)N(R37B)2, C(O)NH2, C(O)NHR37B, C(O)N(R37B)2, C(O)NHOH, C(O)NHOR37B, C(O)NHSO2R37B, C(O)NR37BSO2R37B, SO2NH2, SO2NHR37B, SO2N(R37B)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR37B, C(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R37B je alkil, alkenil, alkinil ili R37C; R37C je fenil, heteroaril, cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil; Z3 je R38, R39 ili R40; R38 je fenil koji je nestaljen ili staljen s R38A; R38A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R39 je heteroaril koji je nestaljen ili staljen s R39A; R39A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R40 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R40A; R40A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; pri čemu su ciklički ostaci molekula, koji su predstavljeni preko E1 i Y1 zajedno, Y1 i B1 zajedno, A2 i B1 zajedno, A2 i D1 zajedno, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R28, R28A, R29, R29A, R30, R30A, R38, R38A, R39, R39A, R40 i R40A, neovisno nesupstituirani, supstituirani ili dodatno supstituirani s jednim ili dva ili tri ili četiri ili pet supstituenata neovisno odabranih od R57A, R57, OR57, SR57, S(O)R57, SO2R57, C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, NHR57, N(R57)2, NHC(O)R57, NR57C(O)R57, NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)NHR57, NHC(O)N(R57)2, NR57C(O)NHR57, NR57C(O)N(R57)2, C(O)NH2, C(O)NHR57, C(O)N(R57)2, C(O)NHOH, C(O)NHOR57, C(O)NHSO2R57, C(O)NR57SO2R57, SO2NH2, SO2NHR57, SO2N(R57)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR57, C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R57A je spiroalkil; R57 je R58, R59, R60 ili R61; R58 je fenil koji je nestaljen ili staljen s R58A; R58A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R59 je heteroaril koji je nestaljen ili staljen s R59A; R59A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R60 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R60A; R60A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R61 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R62, OR62, SR62, S(O)R62, SO2R62, C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, NHR62, N(R62)2, NHC(O)R62, NR62C(O)R62, NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)NHR62, NHC(O)N(R62)2, NR62C(O)NHR62, NR62C(O)N(R62)2, C(O)NH2, C(O)NHR62, C(O)N(R62)2, C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62, C(O)NR62SO2R62, SO2NH2, SO2NHR62, SO2N(R62)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR62, C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R62 je R63, R64, R65 ili R66; R63 je fenil koji je nestaljen ili staljen s R63A; R63A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R64 je heteroaril koji je nestaljen ili staljen s R64A; R64A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R65 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R65A; R65A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R66 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R67, OR67, SR67, S(O)R67, SO2R67, C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, NHR67, N(R67)2, NHC(O)R67, NR67C(O)R67, NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)NHR67, NHC(O)N(R67)2, NR67C(O)NHR67, NR67C(O)N(R67)2, C(O)NH2, C(O)NHR67, C(O)N(R67)2, C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67, C(O)NR67SO2R67, SO2NH2, SO2NHR67, SO2N(R67)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR67, C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R67 je alkil, alkenil, alkinil, fenil, heteroaril, cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil; pri čemu su ciklički ostaci molekula, koji su predstavljeni s R57A, R58, R59, R60, R63, R64, R65 i R67, nesupstituirani ili supstituirani s jednim ili dva ili tri ili četiri supstituenta neovisno odabrana od R68, OR68, SR68, S(O)R68, SO2R68, C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, NHR68, N(R68)2, NHC(O)R68, NR68C(O)R68, NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)NHR68, NHC(O)N(R68)2, NR68C(O)NHR68, NR68C(O)N(R68)2, C(O)NH2, C(O)NHR68, C(O)N(R68)2, C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68, C(O)NR68SO2R68, SO2NH2, SO2NHR68, SO2N(R68)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR68, C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R68 je R69, R70, R71 ili R72; R69 je fenil koji je nestaljen ili staljen s R69A; R69A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R70 je heteroaril koji je nestaljen ili staljen s R70A; R70A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R71 je cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil, od kojih je svaki nestaljen ili staljen s R71A; R71A je benzen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; R72 je alkil, alkenil ili alkinil, od kojih je svaki nesupstituiran ili supstituiran s jednim ili dva ili tri supstituenta neovisno odabrana od R73, OR73, SR73, S(O)R73, SO2R73 C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73, NH2, NHR73, N(R73)2, NHC(O)R73, NR73C(O)R73, NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)NHR73, NHC(O)N(R73)2, NR73C(O)NHR73, NR73C(O)N(R73)2, C(O)NH2, C(O)NHR73, C(O)N(R73)2, C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73, C(O)NR73SO2R73, SO2NH2, SO2NHR73, SO2N(R73)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR73, C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br i I; R73 je alkil, alkenil ili alkinil, fenil, heteroaril, cikloalkil, cikloalkenil, heterocikloalkil ili heterocikloalkenil; i pri čemu su ostaci molekula, koji su predstavljeni s R69, R70, i R71, nesupstituirani ili supstituirani s jednim ili dva ili tri ili četiri supstituenta neovisno odabrana od NH2, C(O)NH2, C(O)NHOH, SO2NH2, CF3, CF2CF3, C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, OCF3, OCF2CF3, F, Cl, Br i I.
2. Spoj ili terapeutski prihvatljiva sol prema patentnom zahtjevu 1, naznačen time, da je: 4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-{4-[(4’-kloro-1,1’-bifenil-2-il)metil]piperazin-1-il}-N-({4-[(3-morfolin-4-ilpropil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(1-tetrahidro-2H-piran-4-ilpiperidin-4-il)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(1-metilpiperidin-4-il)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-metilpiperazin-1-il)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2-metoksietil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-nitro-4-{[(3S)-tetrahidro-2H-piran-3-ilmetil]amino}fenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[4-(1,4-dioksan-2-ilmetoksi)-3-nitrofenil]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-nitro-4-{[(3R)-tetrahidro-2H-piran-3-ilmetil]amino}fenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-(2-naftilsulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2-metoksietil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[3-nitro-4-(tetrahidro-2H-piran-4-ilmetoksi)fenil]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(1,4-dioksan-2-ilmetil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(2,2,2-trifluoroetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(3,3,3-trifluoropropil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2S)-1,4-dioksan-2-il-metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; cis-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(4-metoksi-cikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2R)-1,4-dioksan-2-il-metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({4-[(1,4-dioksan-2-ilmetil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-{[4-(1,4-dioksan-2-ilmetoksi)-3-nitrofenil]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(4-metoksicikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-{[5-cijano-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-cijano-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-fluorotetrahidro-2H-piran-4-il)metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-{[3-(aminokarbonil)-4-(tetrahidro-2H-piran-4-ilmetoksi)fenil]sulfonil}-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; cis-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-il-cikloheksil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-kloro-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-{[5-kloro-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)-N-{[4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-(trifluorometil)fenil]sulfonil}benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamid; trans-4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil{piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({4-[(1-metilpiperidin-4-il)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 5-({[4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzoil]amino}sulfonil)-2-(tetrahidro-2H-piran-4-ilmetoksi)nikotinamid; N-({5-bromo-6-[(1-metilpiperidin-4-il)metoksi]piridin-3-il}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetil-cikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(1-metilpiperidin-4-il)metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-cijano-6-(1,4-dioksan-2-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-{[5-bromo-6-(1,4-dioksan-2-ilmetoksi)piridin-3-il]sulfonil}-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2,2-dimetiltetrahidro-2H-piran-4-il)metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-({3-kloro-5-cijano-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-({4-[(1-acetilpiperidin-4-il)amino]-3-nitrofenil}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-({2-kloro-5-fluoro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(3-morfolin-4-ilpropil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({5-cijano-6-[(4-fluorotetrahidro-2H-piran-4-il)metoksi]piridin-3-il}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-cijano-6-(2-morfolin-4-iletoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-[(3-kloro-4-{[2-(2-metoksietoksi)etil]sulfonil}fenil)sulfonil]-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[2-(2-metoksietoksi)etil]sulfonil}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)oksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-({5-bromo-6-[(1-tetrahidro-2H-piran-4-ilpiperidin-4-il)amino]piridin-3-il}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(2-cijanoetil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; cis-4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-N-{[4-({4-[bis(ciklopropilmetil)amino]cikloheksil}amino)-3-nitrofenil]sulfonil}-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(1-metilpiperidin-4-il)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(morfolin-3-ilmetil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-({4-[(4-metil- piperazin-1-il)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilbut-2-inil)oksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-etinil-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sufonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-okso-3,4-dihidrokinazolin-6-il)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[8-(4-klorofenil)spiro[4.5]dek-7-en-7-il]metil}piperazin-1-il)-N-({4-[(4-morfolin-4-ilcikloheksil)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; cis-4-(4-{[4-(4-klorofenil)-6,6-dimetil-5,6-dihidro-2H-piran-3-il]metil}piperazin-1-il)-N-[(4-{[(4-metoksicikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[8-(4-klorofenil)spiro[4.5]dek-7-en-7-il]metil}piperazin-1-il)-N-({4-[(4-fluorotetrahidro-2H-piran-4-il)metoksi]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; trans-4-(4-{[8-(4-klorofenil)spiro[4.5]dek-7-en-7-il]metil}piperazin-1-il)-N-[(4-{[(4-metoksicikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-5,5-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-5,5-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-cijano-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; terc-butil 3-{[4-({[4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzoil]amino}sulfonil)-2-nitrofenoksi]metil}morfolin-4-karboksilat; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[4-(morfolin-3-ilmetoksi)-3-nitrofenil]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[8-(4-klorofenil)spiro[4.5]dek-7-en-7-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[1-(metilsulfonil)piperidin-4-il]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({4-[(1,1-dioksidotetrahidro-2H-tiopiran-4-il)amino]-3-nitrofenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; N-[(4-kloro-3-nitrofenil)sulfonil]-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(3-nitro-4-{[1-(2,2,2-trifluoroetil)piperidin-4-il]amino}fenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({5-cijano-6-[(1-tetrahidro-2H-piran-4-ilpiperidin-4-il)oksi]piridin-3-il}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-{[5-izopropil-6-(tetrahidro-2H-piran-4-ilmetoksi)piridin-3-il]sulfonil}-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; Ili N-({3-kloro-5-fluoro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid; ili njihova terapeutski prihvatljiva sol.
3. Spoj ili terapeutski prihvatljiva sol prema patentnom zahtjevu 1, naznačen time, da je 4-(4-{[2-(4-klorofenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova terapeutski prihvatljiva sol.
4. Spoj ili terapeutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za uporabu u liječenju pacijenta od raka mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, kolorektalnog raka, raka jednjaka, hepatocelularnog raka, limfoblastične leukemije, folikularnog limfoma, limfoidne malignosti s izvorištem u T stanici ili B stanici, melanoma, mijelogene leukemije, raka usta, raka jajnika, raka pluća nemalih stanica, mijeloma, raka prostate, raka pluća malih stanica ili raka slezene.
5. Farmaceutski pripravak, naznačen time, da sadrži pomoćno sredstvo i spoj ili terapeutski prihvatljivu sol prema bilo kojem od patentnih zahtjeva 1 do 3.
6. Spoj ili terapeutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da se upotrebljava kao lijek.
HRP20151001TT 2009-05-26 2010-05-26 Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti HRP20151001T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18120309P 2009-05-26 2009-05-26
PCT/US2010/036198 WO2010138588A2 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP10721246.6A EP2435432B3 (en) 2009-05-26 2010-05-26 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Publications (2)

Publication Number Publication Date
HRP20151001T1 HRP20151001T1 (hr) 2015-10-23
HRP20151001T4 true HRP20151001T4 (hr) 2024-02-16

Family

ID=42677657

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151001TT HRP20151001T4 (hr) 2009-05-26 2010-05-26 Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti

Country Status (43)

Country Link
US (1) US8580794B2 (hr)
EP (3) EP3656771A1 (hr)
JP (7) JP5747025B2 (hr)
KR (8) KR20190130676A (hr)
CN (5) CN109966294A (hr)
AR (2) AR076705A1 (hr)
AU (1) AU2010254160C1 (hr)
BR (2) BRPI1014359B1 (hr)
CA (4) CA3052016A1 (hr)
CL (1) CL2011002949A1 (hr)
CO (1) CO6480950A2 (hr)
CR (2) CR20170019A (hr)
CY (2) CY1117423T1 (hr)
DK (1) DK2435432T6 (hr)
DO (1) DOP2011000367A (hr)
EC (1) ECSP11011554A (hr)
ES (1) ES2546294T3 (hr)
FI (1) FI2435432T6 (hr)
HK (2) HK1163099A1 (hr)
HR (1) HRP20151001T4 (hr)
HU (2) HUE027698T2 (hr)
IL (5) IL299019A (hr)
LT (1) LTC2435432I2 (hr)
ME (1) ME02205B (hr)
MX (2) MX339469B (hr)
MY (1) MY155645A (hr)
NL (1) NL300873I2 (hr)
NO (1) NO2017023I1 (hr)
NZ (1) NZ595708A (hr)
PE (1) PE20120345A1 (hr)
PH (1) PH12015500297A1 (hr)
PL (1) PL2435432T6 (hr)
PT (1) PT2435432E (hr)
RS (1) RS54234B2 (hr)
RU (3) RU2535347C3 (hr)
SG (2) SG175253A1 (hr)
SI (1) SI2435432T2 (hr)
SM (1) SMT201500225B (hr)
TW (3) TWI537269B (hr)
UA (1) UA106079C2 (hr)
UY (3) UY32668A (hr)
WO (1) WO2010138588A2 (hr)
ZA (1) ZA201108616B (hr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744711C (en) * 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PL2511264T3 (pl) * 2009-01-19 2015-08-31 Abbvie Inc Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ME02205B (me) * 2009-05-26 2016-02-20 Abbvie Bahamas Ltd INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
KR20180059560A (ko) * 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
UY33746A (es) 2010-11-23 2012-06-29 Abbott Lab Método de tratamiento que usa inhibidores selectivos de bcl-2
AU2011332043C1 (en) * 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9108910B2 (en) 2011-02-15 2015-08-18 Ube Industries, Ltd. Industrial methods for producing arylsulfur pentafluorides
CN102241649A (zh) * 2011-07-08 2011-11-16 陈飞 3-四氢呋喃甲醇的制备方法
US8940737B2 (en) 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CN104736153B (zh) * 2012-08-13 2018-06-29 艾伯维公司 细胞凋亡诱导剂
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
HUE040126T2 (hu) * 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6575952B2 (ja) * 2013-04-08 2019-09-18 ファーマサイクリックス エルエルシー イブルチニブ併用療法
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
HUE056329T2 (hu) 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
NZ768373A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
EP3319995B1 (en) 2015-07-07 2019-04-17 H. Hoffnabb-La Roche Ag Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
WO2017063572A1 (zh) * 2015-10-13 2017-04-20 苏州晶云药物科技有限公司 细胞凋亡诱导剂的新晶型及其制备方法
JP6944936B2 (ja) 2015-12-04 2021-10-06 ポートラ ファーマシューティカルズ， インコーポレイテッド 血液癌を処置するためのセルデュラチニブ
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017157813A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for the treatment of hematological malignancies
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR102447884B1 (ko) 2016-04-21 2022-09-27 바이오벤처스, 엘엘씨 항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
EP3494115B1 (en) * 2016-08-05 2020-10-21 The Regents of The University of Michigan N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
CN109641897B (zh) * 2016-09-01 2021-12-07 北京赛林泰医药技术有限公司 Bcl-2选择性抑制剂及其制备和用途
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN110177788B (zh) * 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
WO2018167652A1 (en) * 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN110546151B (zh) * 2017-04-18 2023-04-28 重庆复创医药研究有限公司 凋亡诱导剂
CN107089981A (zh) * 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN110759908B (zh) * 2017-06-26 2021-03-12 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
EP3658188A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
KR20200090738A (ko) 2017-08-23 2020-07-29 뉴에이브 파마슈티칼 인크. 신생물성 질환의 치료를 위한 bcl-2 억제제로서의 축합된 헤테로시클릭 유도체
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
CN111801320A (zh) 2018-01-10 2020-10-20 里科瑞尔姆Ip控股有限责任公司 苯甲酰胺化合物
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
BR112020016551A2 (pt) 2018-02-16 2020-12-22 Abbvie Inc. Inibidores de bcl-2 seletivos em combinação com anticorpo anti-pd-1 ou anti-pd-l1 para o tratamento de cânceres
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
CN111868059B (zh) * 2018-03-30 2021-12-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN117430601A (zh) * 2018-04-29 2024-01-23 百济神州有限公司 Bcl-2抑制剂
EP3788035A2 (en) 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
TW202023568A (zh) 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
KR20200139139A (ko) * 2018-07-31 2020-12-11 어센테지 파마 (쑤저우) 컴퍼니 리미티드 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과
CA3094449C (en) 2018-07-31 2023-02-28 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US20210315904A1 (en) 2018-08-22 2021-10-14 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3858832A4 (en) * 2018-10-29 2022-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2 SELECTIVE INHIBITOR
CN109438441A (zh) * 2018-11-30 2019-03-08 重庆三圣实业股份有限公司 一种维奈妥拉的制备方法及其产品
CN109320516A (zh) * 2018-11-30 2019-02-12 重庆三圣实业股份有限公司 一种维奈妥拉中间体的制备方法及其产品
WO2020232214A1 (en) 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020234445A1 (en) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor and a bcl-2 inhibitor
CN113825754B (zh) * 2019-05-24 2023-09-22 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN112661751A (zh) * 2019-10-16 2021-04-16 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
US20230002369A1 (en) * 2019-10-28 2023-01-05 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
WO2021219065A1 (zh) * 2020-04-29 2021-11-04 正大天晴药业集团股份有限公司 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
CN114478520A (zh) * 2020-10-28 2022-05-13 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
CN114736203A (zh) * 2021-01-07 2022-07-12 南京天印健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
AR125046A1 (es) 2021-03-19 2023-05-31 Eil Therapeutics Inc Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
CN117377672A (zh) 2021-06-04 2024-01-09 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
KR20240054327A (ko) * 2021-08-31 2024-04-25 베이진 엘티디 Bcl-2 저해제의 고체 형태, 제조 방법 및 이의 용도
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024017354A1 (en) * 2022-07-21 2024-01-25 Beigene, Ltd. Methods of treating multiple myeloma using bcl-2 inhibitor
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
KR102598137B1 (ko) 2022-11-24 2023-11-06 율촌화학 주식회사 고차단성 생분해 필름 및 이의 제조방법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB9110625D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
ATE234270T1 (de) * 1992-12-02 2003-03-15 Pfizer Cathecoldiether als selektive pde iv hemmungsmittel
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
JP3409029B2 (ja) * 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
SK18822000A3 (sk) * 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
JP4234344B2 (ja) * 1999-12-28 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP4167173B2 (ja) 2001-06-06 2008-10-15 イーライ リリー アンド カンパニー 抗腫瘍剤としての使用のためのベンゾイルスルホンアミドおよびスルホンベンズアミジン
US20030059489A1 (en) 2001-09-24 2003-03-27 Canolio Inc. Genital lubricating compositions and uses thereof
AU2002337765A1 (en) * 2001-09-26 2003-04-07 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US6995787B2 (en) 2002-08-21 2006-02-07 Adams Steven L Sports projectile and camera apparatus
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
MXPA06014754A (es) * 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
NZ561609A (en) * 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
JP2008540664A (ja) 2005-05-16 2008-11-20 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピロロピリジン誘導体
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070115787A1 (en) * 2005-11-23 2007-05-24 Seagate Technology Llc Planar optical device for generating optical nanojets
JP5277168B2 (ja) * 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8557983B2 (en) * 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744711C (en) 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
PL2511264T3 (pl) * 2009-01-19 2015-08-31 Abbvie Inc Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
ME02205B (me) * 2009-05-26 2016-02-20 Abbvie Bahamas Ltd INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Also Published As

Publication number Publication date
JP2020023545A (ja) 2020-02-13
JP2017048219A (ja) 2017-03-09
KR20190086591A (ko) 2019-07-22
IL286036A (en) 2021-10-31
UY37825A (es) 2020-02-28
US20110124628A1 (en) 2011-05-26
KR20180049164A (ko) 2018-05-10
NL300873I2 (nl) 2017-10-24
WO2010138588A3 (en) 2011-04-07
AR109974A2 (es) 2019-02-13
CN104876927B (zh) 2017-06-23
KR20230128571A (ko) 2023-09-05
NO2017023I2 (no) 2017-05-29
KR20150065947A (ko) 2015-06-15
IL215644A0 (en) 2012-01-31
ME02205B (me) 2016-02-20
JP6353506B2 (ja) 2018-07-04
WO2010138588A2 (en) 2010-12-02
UY33047A (es) 2011-09-30
ES2546294T3 (es) 2015-09-22
WO2010138588A9 (en) 2011-05-05
CN109897038A (zh) 2019-06-18
EP2435432A2 (en) 2012-04-04
CR20110632A (es) 2012-02-15
IL299019A (en) 2023-02-01
KR20120034671A (ko) 2012-04-12
CN109897038B (zh) 2022-04-05
DK2435432T3 (en) 2015-08-31
JP6038195B2 (ja) 2016-12-07
JP2015110605A (ja) 2015-06-18
RU2535347C3 (ru) 2019-05-14
RU2014132884A (ru) 2015-12-27
AU2010254160B2 (en) 2015-02-12
CY2017019I1 (el) 2018-01-10
KR101659583B1 (ko) 2016-09-29
ZA201108616B (en) 2015-12-23
NZ595708A (en) 2014-03-28
PL2435432T6 (pl) 2024-02-12
PL2435432T3 (pl) 2015-12-31
NO2017023I1 (no) 2017-05-29
CL2011002949A1 (es) 2012-05-25
TWI476195B (zh) 2015-03-11
JP2012528178A (ja) 2012-11-12
JP2018138577A (ja) 2018-09-06
CA2759182A1 (en) 2010-12-02
CY2017019I2 (el) 2018-01-10
SMT201500225B (it) 2015-10-30
CN109966294A (zh) 2019-07-05
IL269092A (en) 2019-11-28
CA3052016A1 (en) 2010-12-02
KR20170037683A (ko) 2017-04-04
BR122019016429B1 (pt) 2020-03-24
RU2628885C2 (ru) 2017-08-22
RS54234B2 (sr) 2024-02-29
IL253891A0 (en) 2017-10-31
EP2944638A1 (en) 2015-11-18
PE20120345A1 (es) 2012-05-17
RU2015154494A (ru) 2017-06-22
TW201107323A (en) 2011-03-01
PH12015500297A1 (en) 2015-12-07
AU2010254160C1 (en) 2023-07-06
LTC2435432I2 (lt) 2018-06-11
CA2759182C (en) 2016-06-07
MX2019012154A (es) 2019-11-21
RU2011152973A (ru) 2013-07-10
KR20180124164A (ko) 2018-11-20
EP3656771A1 (en) 2020-05-27
CR20170019A (es) 2017-05-12
JP5747025B2 (ja) 2015-07-08
SG175253A1 (en) 2011-11-28
TWI537269B (zh) 2016-06-11
CN102448959B (zh) 2015-06-17
KR101723378B1 (ko) 2017-04-06
KR101920202B1 (ko) 2018-11-21
HK1215576A1 (zh) 2016-09-02
RS54234B1 (en) 2015-12-31
MX339469B (es) 2016-05-27
CO6480950A2 (es) 2012-07-16
IL215644A (en) 2017-08-31
CA2929347A1 (en) 2010-12-02
CY1117423T1 (el) 2017-04-26
DOP2011000367A (es) 2017-07-31
SG10201704742YA (en) 2017-07-28
EP2435432B1 (en) 2015-06-24
HUE027698T2 (en) 2016-10-28
SI2435432T2 (sl) 2024-04-30
CN104876927A (zh) 2015-09-02
HUS1700021I1 (hu) 2017-06-28
KR102001418B1 (ko) 2019-07-19
JP2022033939A (ja) 2022-03-02
ECSP11011554A (es) 2012-01-31
US8580794B2 (en) 2013-11-12
UY32668A (es) 2010-12-31
MX2011012257A (es) 2011-12-16
BRPI1014359A2 (pt) 2016-04-05
EP2435432B3 (en) 2023-10-25
AU2010254160A1 (en) 2011-11-24
HK1163099A1 (en) 2012-09-07
SI2435432T1 (sl) 2015-10-30
KR20190130676A (ko) 2019-11-22
UA106079C2 (uk) 2014-07-25
LTPA2017015I1 (lt) 2017-06-12
AR076705A1 (es) 2011-06-29
CA3206963A1 (en) 2010-12-02
TW201607946A (zh) 2016-03-01
TWI561523B (en) 2016-12-11
RU2535347C2 (ru) 2014-12-10
JP2023040165A (ja) 2023-03-22
PT2435432E (pt) 2015-10-13
CN104906100A (zh) 2015-09-16
FI2435432T6 (fi) 2023-11-21
HRP20151001T1 (hr) 2015-10-23
BRPI1014359B1 (pt) 2019-11-05
RU2573832C2 (ru) 2016-01-27
MY155645A (en) 2015-11-13
CN102448959A (zh) 2012-05-09
TW201506025A (zh) 2015-02-16
DK2435432T6 (da) 2023-12-18

Similar Documents

Publication Publication Date Title
HRP20151001T4 (hr) Sredstva kao induktori apoptoze za liječenje raka te imunih i autoimunih bolesti
HRP20161085T1 (hr) Sulfonamid derivati kao bcl-2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti
JP2019038820A5 (hr)
JP2017048219A5 (hr)
CA2735400A1 (en) Piperazine d3 and 5-ht2a receptor modulators
JP2019509276A5 (hr)
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
JP2017504635A5 (hr)
RU2003102612A (ru) N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1
HRP20141094T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
JP2004504301A5 (hr)
RU2015143917A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
JP2005509024A5 (hr)
JP2016505512A5 (hr)
JP2015524472A5 (hr)
JP2013540823A5 (hr)
JP2014530900A5 (hr)
RU2015137103A (ru) Фуропиридины в качестве ингибиторов бромодоменов
JP2005501120A5 (hr)
RU2005137403A (ru) Новые замещенные 3-сера-индолы
JP2012530765A5 (hr)
RU2014115427A (ru) Фармацевтические композиции замещенных хиназолинонов
RU2013132930A (ru) Производное пиразола
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2014148316A (ru) Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы